Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Montefiore Medical Center
Modality
monoclonal_antibody
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06865339CT.gov Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06918132CT.gov Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06161441CT.gov A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery | — | Active Not Recruiting | — | — | — |
NCT05800015CT.gov A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05785767CT.gov A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT03916627CT.gov Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fianlimab (this asset) | Montefiore Medical Center | P2/3 | CCC · 52 |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Endostatin | Henan Cancer Hospital | P4 | BBB |
| Zorifertinib | Alpha Biopharma (Jiangsu) Co., Ltd. | P2/3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Vinorelbine Ditartrate | Intergroupe Francophone de Cancerologie Thoracique | P4 | BB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Fianlimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P3 | CCC · 55 |
| Metastatic Melanoma | — | P2 | CCC · 52 |
| Primary Peritoneal Carcinoma | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fianlimab in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fianlimab-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →